Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126632751 | 12663275 | 1 | I | 2016 | 20160808 | 20160818 | 20160818 | EXP | US-TEVA-685024USA | TEVA | 62.02 | YR | F | Y | 0.00000 | 20160818 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126632751 | 12663275 | 1 | PS | COPAXONE | GLATIRAMER ACETATE | 1 | Subcutaneous | X08921 | 20622 | 20 | MG | INJECTION | QD | ||||||
| 126632751 | 12663275 | 2 | C | AMPYRA | DALFAMPRIDINE | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 3 | C | ONDANSETRON | ONDANSETRON | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 4 | C | MODAFINIL. | MODAFINIL | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 5 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 6 | C | TAMSULOSIN | TAMSULOSIN | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 7 | C | DILTIAZEM. | DILTIAZEM | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 8 | C | XARELTO | RIVAROXABAN | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 9 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 10 | C | METOPROLOL. | METOPROLOL | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 11 | C | ATENOLOL. | ATENOLOL | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 12 | C | GABAPENTIN. | GABAPENTIN | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 13 | C | DIOVAN | VALSARTAN | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 14 | C | HCTZ | HYDROCHLOROTHIAZIDE | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 15 | C | POTASSIUM | POTASSIUM | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 16 | C | BACLOFEN. | BACLOFEN | 1 | 0 | ||||||||||||
| 126632751 | 12663275 | 17 | C | PROVIGIL | MODAFINIL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126632751 | 12663275 | 1 | Multiple sclerosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126632751 | 12663275 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126632751 | 12663275 | Abdominal discomfort | |
| 126632751 | 12663275 | Drug dose omission | |
| 126632751 | 12663275 | Nausea | |
| 126632751 | 12663275 | Palpitations |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126632751 | 12663275 | 1 | 20140102 | 0 |